EPA Addresses Microplastics, PFAS in Drinking Water; HHS to Study Microplastics in Humans

Why It Matters

Adding these contaminants to CCL 6 signals potential future drinking‑water regulations and highlights growing health concerns around microplastics and PFAS. The HHS program could create the first clinical standards for assessing and mitigating plastic exposure in humans.

Key Takeaways

• EPA adds microplastics, PFAS, pharmaceuticals to CCL 6
• 30 million U.S. water users exceed rescinded PFAS limits
• HHS launches $144 M STOMP program for human microplastics
• EPA to finalize CCL‑6 by November 17, 2026
• Phase 1 targets measurement and risk stratification of MNPs

Pulse Analysis

The Environmental Protection Agency’s update to the Contaminant Candidate List reflects a broader shift toward addressing emerging pollutants in public water systems. By formally recognizing microplastics, PFAS, and pharmaceuticals, the agency is laying groundwork for future Safe Drinking Water Act rules. The CCL process, updated every five years, serves as a scouting report for regulators, and the inclusion of these groups signals that data collection and risk assessment will intensify, especially after the recent rollback of PFAS limits that left millions of consumers without enforceable protections.

For water utilities, the draft CCL 6 introduces operational uncertainty but also an opportunity to pre‑emptively adopt advanced treatment technologies. The estimate that 30 million Americans receive water exceeding the rescinded PFAS thresholds underscores the urgency for infrastructure upgrades and tighter monitoring. Stakeholders now have a 60‑day comment window, during which industry, NGOs, and scientists can influence the prioritization of contaminants, potentially shaping the scope of future compliance requirements and funding allocations for remediation projects.

The Department of Health and Human Services’ STOMP initiative complements EPA’s regulatory focus by targeting the human health side of microplastic exposure. With $144 million earmarked for measurement methods, risk stratification, and eventual removal techniques, the program aims to create a clinical test for individual microplastic burden. This could transform public health surveillance, inform risk‑based guidelines, and drive cross‑agency collaboration. Together, EPA’s CCL expansion and HHS’s research investment signal a coordinated federal response that may accelerate both regulatory action and scientific breakthroughs in the fight against pervasive water‑borne contaminants.